Cannasouth was New Zealand’s first medicinal cannabis company to list on the New Zealand Stock Exchange (NZX:CBD) in June 2019. We are a vertically integrated biopharmaceutical company dedicated to advanced product development and research. Our goal is to develop next-generation medicinal cannabis products for prescribers and patients in New Zealand and export these pharmaceutical quality products and technologies globally.

We will produce our cannabis-based medicines and ingredients using cannabinoid extracts from high-quality, medical-grade cultivars. These medicines will be manufactured under GACP and GMP regulations using environmentally friendly methods, ensuring patients are treated with sophisticated medicines made of pure therapeutic compounds of the highest quality.